结肠炎丸治疗老年溃疡性结肠炎疗效观察

溃疡性结肠炎病因比较复杂 ,病程迁延 ,易复发 ,目前尚无特效治疗方法。我们近年内使用结肠炎丸治疗老年性溃疡性结肠炎 34例 ,并与柳氮磺胺吡啶 (ＳＡＳＰ)进行对照观察 ,现将结果报道如下。1　对象与方法1 1　病例选择　本组病例为我院 1995～1999年收治溃疡性结肠炎 12 6例 ,其中老年溃疡性结肠炎 6 4例。溃疡性结肠炎诊断符合 1993年太原全国慢性非感染性肠道疾病学术研讨会所规定的溃疡性结肠炎诊断标准。 6 4例中男 42例 ,女 2 2例 ,年龄 6 0～ 74岁 ,平均 ( 6 4 5± 0 6 )岁。初发型 15例 ,慢性复发型 19例 ,慢性持续型 30例。病程 …     

中西药结合治疗慢性溃疡性结肠炎近期疗效观察

慢性非特异性溃疡性结肠炎（UC）至今病因不明，治疗方法各异。我们2000～2004年共收治85例，采用灌肠治疗收到良好效果，现总结报告如下。     

选择性白细胞吸附疗法治疗溃疡性结肠炎的疗效及安全性分析

目的探讨选择性白细胞吸附疗法(granulocyte and monocyte adsorption apheresis,GMA)治疗溃疡性结肠炎(ulcerative colitis,UC)的疗效及安全性。方法回顾性收集2018年5月至2019年5月在山东中医药大学第二附属医院行GMA治疗的18例UC患者的临床资料,所有入组患者均行1周2次、5次为1个疗程的治疗方案,重度患者适当延长疗程,分析治疗前、治疗1个疗程后的内镜检查、改良Mayo评分、红细胞沉降率(ESR)、C-反应蛋白(CRP)、白细胞计数(WBC)、中性粒细胞计数(NEUT)、白蛋白(ALB)、血红蛋白(HGB),同时观察患者治疗后的不良反应。结果与治疗前比较,GMA治疗1个疗程结束后,改良Mayo评分、ESR、CRP均显著降低(P<0.05),ALB、HGB均显著升高(P<0.05),WBC、NEUT差异无统计学意义(P>0.05)。18例患者在GMA治疗过程中及治疗后均无明显不良反应发生,安全性良好。结论GMA可明显降低炎症活动度及改善临床症状,且不良反应发生率较低,具有良好的疗效及安全性。     

赛霉安保留灌肠治疗溃疡性结肠炎近期疗效观察

目的 观察赛霉安保留灌肠治疗轻、中度溃疡性结脾性炎的疗效。方法 对３２例轻、中度未端溃疡性结肠炎病人随机分赛霉安治疗组（２０例）和地塞米松治疗组（１２例）中肠治疗１疗程后评估疗效。结果 症状缓解率和内镜缓解率赛霉安治疗组均迷９０％（１８／２０）,地塞米松治疗组为３８．３％（１０／１２）,两组差异无显著性意义（Ｐ〉０．０５）。结论 赛霉安是一种纯中药制剂,局部治疗轻、中度溃疡性结肠炎有较好疗效。与地     

洛赛克,泰胃美与钙通道阻滞剂治疗消化性溃疡的近期与远期疗效观察

用洛赛克、泰胃美及钙通道阻滞剂治疗127例经胃镜证实的活动性消化性溃疡。洛赛克组(简称洛组)35例,每晨服20mg,疗程4～6周。泰胃美组(简称泰组)32例,每晚服800mg,疗程为8周。钙通道阻滞剂组(简称CCBA组)60例,服硝苯啶10mg,tid或尼莫地平20mg tid,CCBA组分为CCBA-Ⅰ组(疗程为8周)和CCBA-Ⅱ组(长期用药)。洛组、泰组、CCBA组的溃疡痊率分别为97.1％,87.5％,83.3％。洛组、泰组、CCBA-Ⅰ组的6个月复发率分别为23.5％,32.1％,34.6％,12个月复发率分别为35.3％,71.4％,73.1％。长期服药的CCBA-Ⅱ组6个月内无复发,12个月内仅1例复发。上述结果提示洛赛克是治疗消化性溃疡非常有效的药物,而钙通道阻滞剂长期服用能有效地预防溃疡复发。     

钙通道阻滞剂治疗肝纤维化的研究进展

关于钙通道阻滞剂(calcium-channel blocker,CCB)预防和治疗肝纤维化的研究,国外仅见Cutrin报道了硝苯吡啶对大鼠实验性肝纤维化的初步作用,国内通过实验与临床研究,发现CCB在减轻肝脏炎症与肝细胞损伤、干扰细胞外基质产生并增加其分解、抑制储脂细胞增殖与转化及抑制成纤维细胞DNA与蛋白质合成等方面具有较好的作用,本文就此作一综述。 1 对血清PⅢP及PCⅢ的影响 血清PⅢP来源于Ⅲ型前胶原,在胶原合成旺盛时,血清PⅢP含量升高,是目前研究最多的反映肝纤维化的指标。多数研究表明,血清PⅢP能较好地反映肝纤维组织生成的     

钙通道阻滞剂在肝硬化治疗中的应用

钙通道阻滞剂在肝硬化治疗中的应用西安医科大学第一临床医学院消化内科许君望综述段仲璧审校钙通道阻滞剂（ＣａｌｃｉｕｍＣｈａｎｎｅｌＢｌｏｃｋｅｒ，ＣＣＢ）在心血管及呼吸系统被广泛应用，八十年代后人们不断发现ＣＣＢ在消化系统的应用价值，近年来在肝病，特别...     

中药治疗慢性溃疡性结肠炎疗效分析

近3年来,我们应用中药煎剂内服加保留灌肠治疗溃疡性结肠炎,取得满意疗效,现报告如下.资料与方法1.1 临床资料:全部病例均为我院住院患者,均符合文献[1]标准.患者以持续或反复腹痛、腹泻、粘液脓血便为主证,经纤维结肠镜检查肠粘膜充血、水肿、糜烂、溃疡,大便涂片及培养排除其他病原体.将收集的100例病例随机分为治疗组和对照组.治疗组50例,男27例,女23例;年龄20～63岁,平均39.8岁;病程1～20年,平均5.63年.辨证分型:按兼证的不同,分为大肠湿热型16例,脾胃虚弱型19例,气滞血瘀型15例.对照组50例,男28例,女22例;年龄18～64岁,平均40.6岁;病程1～21年,平均5.85年.两组临床资料比较无显著性差异,具有可比性.     

The efficacy and safety of selective leukocytapheresis in the treatment of ulcerative colitis: a meta-analysis

Purpose  

The use of selective leukocytapheresis for the treatment of ulcerative colitis (UC) has been evaluated in several open and controlled trials, with varying outcomes. A meta-analysis was performed to better assess the efficacy and safety of selective leukocytapheresis as supplemental therapy compared with conventional pharmacotherapy in patients with UC.     

Infliximab efficacy in pediatric ulcerative colitis

BACKGROUND: The effects of infliximab, a tumor necrosis factor-alpha (TNF-alpha) antibody, have been well established in adult patients with inflammatory and fistulizing Crohn's disease. This study evaluates short- and long-term efficacy of infliximab in children with ulcerative colitis. METHODS: All pediatric patients with ulcerative colitis who received infliximab between July 2001 and November 2003 at the Johns Hopkins Children's Center were identified. Short- and long-term outcomes and adverse reactions were evaluated. RESULTS: Twelve pediatric patients with ulcerative colitis received infliximab for treatment of fulminant colitis (3 patients), acute exacerbation of colitis (3), steroid-dependent colitis (5), and steroid-refractory colitis (1). Nine patients had a complete short-term response, and 3 had partial improvement. The mean per patient dose of corticosteroid after the first infliximab infusion decreased from 45 mg/day at the first infusion to 22.2 mg/day at 4 weeks (P = 0.02) and 7.8 mg/day at 8 weeks (P = 0.008). Eight patients were classified as long-term responders with a median follow-up time of 10.4 months. Of the 4 long-term nonresponders, 3 underwent colectomy, and the fourth has ongoing chronic symptoms. Three of 4 long-term nonresponders were steroid-refractory compared with 1 of 8 long-term responders. Patients receiving 6-mercaptopurine had a better response to infliximab. CONCLUSION: Infliximab should be considered in the treatment of children with symptoms of acute moderate to severe ulcerative colitis.     

巴柳氮钠治疗活动性溃疡性结肠炎的疗效观察

目的探讨巴柳氮钠（商品名：贝乐司）治疗活动性溃疡性结肠炎（UC）的临床疗效。方法收集2005年10月-2006年6月在河南省16家医院治疗的活动性UC患者139例，随机分为治疗组（n=78）和对照组（n=61）。治疗组患者服用巴柳氮钠片剂每天6g，连续4周，缓解后改为每天2g，继续4周；对照组服用柳氮磺胺吡啶（SASP）片剂每天4g，连续4周，缓解后改为每天2g，继续4周。比较治疗前后两组患者的临床症状（腹痛、腹泻、脓血便）、生化和免疫学指标（肝功能、肾功能、红细胞沉降率、C反应蛋白），以及结肠镜下黏膜和组织学表现。结果治疗后8周，发现巴柳氮钠与SASP均可有效控制UC患者的病情发作（总有效率为84．2％比76．7％，P〉0．05）。在治疗2周后，巴柳氮钠比SASP能更迅速地缓解患者的临床症状，如腹痛（42．1％比69．8％）、腹泻（23．1％比55．6％）和脓血便（58．3％比76．5％），并可改善内镜下黏膜炎症表现及降低黏膜组织炎症分级（P〈0．05）。患者服用巴柳氮钠的依从性好。该药对患者的肝、肾功能无影响，治疗后血细胞沉降率和C反应蛋白的水平均显著降低（P〈0．05），且不良反应发生率亦明显低于SASP（P〈0．01）。结论巴柳氮钠是一种良好的控制UC活动性的药物，能维持病情缓解，不良反应少。     

Long-term treatment of hypertension with the calcium channel blocker diltiazem

A group of 48 patients with essential mild to moderate hypertension were treated with the calcium-channel blocker diltiazem (90-270 mg/day) for one year. Adequate blood pressure control was achieved in all patients. No tolerance developed during the one-year treatment period. The drug is almost free from side effects. Very few patients develop fluid retention, which can be controlled by adding a diuretic.     

CACNA1C基因多态性与钙通道阻滞剂降压疗效的关系

目的 探讨L型钙离子通道 alc 哑基基因(CACNAlC)多态性对钙离子通道阻滞剂治疗原发性高血压(EH)患者疗效的影响.方法 对103例EH患者,给单一硝苯地平缓释片进行6周的治疗,采用多重聚合酶链反应方法(Multi-PCR)及基质辅助激光解析-飞行时间质谱分析技术(MLDI-TOF MS)对 rs216008、rs1051375、rs2299661、rs10848683、rs215976进行分型,分析不同基因型间治疗前后血压变化的差值.结果(1)与治疗前相比,硝苯地平缓释片治疗后所有患者平均收缩压和舒张压均出现明显下降(P＜0.05).(2)rs2299661的CC型舒张压下降幅度明显高于CG型和GG型[(12.46±7.91)mm Hg(1 mm Hg =0.133 kPa)比(7.22±8.01)mm Hg和(5.93±9.77)mm Hg,P＜0.05].(3)rs216008的CC型收缩压下降幅度明显高于CT型[(20.60±12.35)mm Hg比(13.62±10.21)mm Hg,P＜0.05],但与TT型比较差异无统计学意义.(4)rs1051375、rs10848683、rs215976的各基因型间血压变化差值无统计学意义.结论 CACNAI C rs2299661、rs216008的CC型可能会使硝苯地平缓释片治疗EH患者的疗效具更为突出.     

The calcium channel blocker controversy.

A major controversy about the safety of calcium channel blockers (CCBs) has arisen since the publication of a case-control study showing that hypertensives who suffered an acute myocardial infarction (MI) were more likely than hypertensives who had not had an MI to be taking one of these (short-acting) agents than other antihypertensive agents. This study was accompanied by a republication of older studies showing that large doses of short-acting nifedipine given to post-MI patients increased their mortality rate. The danger of massive doses of short-acting nifedipine in a post-MI patient is real but irrelevant to current practice. On the other hand, the putative dangers of short-acting CCBs in the treatment of hypertension do not apply to the current use of long-acting CCBs. Therefore the scare over their use is both irrational and unfortunate.